The National Agency for Food and Drug Administration and Control has alerted the public to the circulation of suspected counterfeit medicinal products mimicking Forxiga (dapagliflozin) in the Nigerian market, warning that their use could pose serious health risks.
NAFDAC said the suspected counterfeit products were detected in the Nigerian market following market surveillance by pharmaceutical company AstraZeneca.
This was disclosed in Public Alert No. 036/2026 posted on the agency’s X handle on Thursday.
According to the notice, AstraZeneca notified the agency after identifying products bearing names closely resembling Forxiga® and imitating the company’s brand identity and logo.
NAFDAC explained that genuine Forxiga® (dapagliflozin) is prescribed to improve blood sugar control in people with Type 2 diabetes, reduce cardiovascular deaths and hospitalisations in patients with heart failure, and slow the progression of chronic kidney disease.
